We are already helping hundreds of customers rapidly scale development and production to accelerate delivery of SARS-CoV-2 vaccines and therapies by providing flexible bioprocessing tools and solutions, outsourcing services, a global manufacturing and supply network, and technical partnership.
Webinar—how can we accelerate delivery together in the next stage of battling SARS-CoV-2?
The vaccine and biotherapeutic manufacturing industries are under pressure to address critical challenges of speed, scale, and supply in its response to SARS-CoV-2. What does this mean for technologies enabling production and how does this impact the future of vaccine and biotherapeutic manufacturing?
During this on-demand webinar, our panel of experts provide insights on challenges facing the industry and how they impact success.
Since the start of the SARS-CoV-2 outbreak, drug developers across the world have been working diligently to respond. Under pressure to accelerate development, they’ve been able to rely on Thermo Fisher Scientific for robust solutions and partnerships.
mRNA manufacturing webinar
This webinar provides an industry overview from a leading provider of RNA technology products and discusses products available for the manufacture of mRNA.
Our upstream and downstream Single-Use technologies including Bioreactors, Mixers and flexible and rigid storage and shipping solutions are enabling our vaccine customers to optimise and accelerate production.
The Single-Use Technologies (SUT) business
Part of our BioProduction Division, is helping our customers in their fight against SARS-CoV-2 by providing assurance of supply. This video discusses our escalation routes through the Coronavirus Command Centre, our SUT capacity expansions and contains a customer testimonial from AGC Biologics.
Innovations in viral vector development, scale up and production
Watch this educational webinar and learn how recent innovation can help you to significantly push the boundaries of viral vectors productivity and quality. Discover how recent innovation in areas such as cells, media and transfection agents can boost and standardise your process, as illustrated by our lentiviral case study.